Loading...
StateHouse Holdings Inc.
STHZ.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.03
CA$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $25.34M in Q2 2023 to $27.77M in Q2 2024. Gross profit continued to perform well, with margins at 53% in the latest quarter. Operating income reached $3.35M in Q2 2024, holding a steady 12% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $5.20M. Net income rose to $208708.00, keeping EPS at $0.001. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan